$1.52
-0.06-3.8%
Last update: Oct 30, 6:37 PM
Autolus Therapeutics PLC
AUTLNASDAQ
Autolus Therapeutics (AUTL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Autolus Therapeutics (AUTL) last issued guidance on August 11, 2026 for fiscal year 2026. The company guided revenue in the range of $140M - $150M for the period.
Compared to prior guidance, Autolus Therapeutics maintained its revenue forecast from a prior range of $140M - $150M.
Autolus Therapeutics has issued 3 guidance updates between May 14, 2026 and August 11, 2026. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.19 | $-0.27 | $-0.38 | $-0.23 |
| Actual | $-0.15 | $-0.27 | $-0.34 | $-0.30 |
| Surprise | +21.1% | 0.00% | +10.5% | -30.4% |
| Revenue | ||||
| Estimate | $41.1M | $26.2M | $23.2M | $22.5M |
| Actual | $45.7M | $26.2M | $24.3M | $21.2M |
| Surprise | +11.1% | +0.22% | +4.51% | -5.68% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.18 | $-0.18 | $-0.19 | $-0.19 |
| Revenue | ||||
| Consensus | $39.8M | $37.7M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.15 | $-0.19 | 21.1 % |
| Q1 | May 14, 2026 | $-0.27 | $-0.27 | 0.00 % |
| Q4 | Mar 27, 2026 | $-0.34 | $-0.38 | 10.5 % |
| Q3 | Nov 12, 2025 | $-0.30 | $-0.23 | -30.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $45.69M | $41.14M | 11.1 % |
| Q1 | May 14, 2026 | $26.22M | $26.16M | 0.22 % |
| Q4 | Mar 27, 2026 | $24.29M | $23.24M | 4.51 % |
| Q3 | Nov 12, 2025 | $21.19M | $22.47M | -5.68 % |
